Bsense Bio Therapeutics is developing small molecules that simultaneously target two pain sensation related ion channels. The two channels, TRPV1 and Kv7.2/3, are co-localized on sensory neurons, and the dual-targeting approach allows increased efficacy as well as safety. The two targeted channels are generally related to neuronal hyperexcitability and their modulation may also be effective in additional indications.

link to BSense Bio page

Neuropathic Pain

Prof. Bernard Attali – Inventor

Haim Belinson, PhD – CSO